CN Patent

CN112661753B — 一种帕布昔利布中间体的制备方法

Assigned to Shandong Baoyuan Pharmaceutical Co ltd · Expires 2022-06-03 · 4y expired

What this patent protects

本发明公开了一种帕布昔利布中间体的制备方法，利用2‑氯‑8‑环戊基‑5‑甲基吡啶并[2,3‑D]嘧啶‑7(8H)‑酮为原料，通过草酸和醋酸酐催化通过NBS溴化，降温析晶离心可以获得6‑溴‑2‑氯‑8‑环戊基‑5‑甲基吡啶并[2,3‑D]嘧啶‑7(8H)‑酮，同时对制备过程中产生的废液进行充分再利用减少三废产生，提供了一条高质量、低成本、对环境友好、适合工业化生产的制备方法。

USPTO Abstract

本发明公开了一种帕布昔利布中间体的制备方法，利用2‑氯‑8‑环戊基‑5‑甲基吡啶并[2,3‑D]嘧啶‑7(8H)‑酮为原料，通过草酸和醋酸酐催化通过NBS溴化，降温析晶离心可以获得6‑溴‑2‑氯‑8‑环戊基‑5‑甲基吡啶并[2,3‑D]嘧啶‑7(8H)‑酮，同时对制备过程中产生的废液进行充分再利用减少三废产生，提供了一条高质量、低成本、对环境友好、适合工业化生产的制备方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN112661753B
Jurisdiction
CN
Classification
—
Expires
2022-06-03
Drug substance claim
No
Drug product claim
No
Assignee
Shandong Baoyuan Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.